- Home
- PAMT vs ELDN Comparison
PAMT vs ELDN Comparison
Compare PAMT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- ELDN
- Stock Information
- Founded
- PAMT 1980
- ELDN 2004
- Country
- PAMT United States
- ELDN United States
- Employees
- PAMT N/A
- ELDN N/A
- Industry
- PAMT Trucking Freight/Courier Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- ELDN Health Care
- Exchange
- PAMT Nasdaq
- ELDN Nasdaq
- Market Cap
- PAMT 356.4M
- ELDN 288.5M
- IPO Year
- PAMT 1985
- ELDN N/A
- Fundamental
- Price
- PAMT $16.64
- ELDN $4.02
- Analyst Decision
- PAMT
- ELDN Strong Buy
- Analyst Count
- PAMT 0
- ELDN 1
- Target Price
- PAMT N/A
- ELDN $16.00
- AVG Volume (30 Days)
- PAMT 42.0K
- ELDN 538.0K
- Earning Date
- PAMT 01-30-2025
- ELDN 11-12-2024
- Dividend Yield
- PAMT N/A
- ELDN N/A
- EPS Growth
- PAMT N/A
- ELDN N/A
- EPS
- PAMT N/A
- ELDN N/A
- Revenue
- PAMT $728,284,000.00
- ELDN N/A
- Revenue This Year
- PAMT N/A
- ELDN N/A
- Revenue Next Year
- PAMT $4.86
- ELDN N/A
- P/E Ratio
- PAMT N/A
- ELDN N/A
- Revenue Growth
- PAMT N/A
- ELDN N/A
- 52 Week Low
- PAMT $13.51
- ELDN $1.52
- 52 Week High
- PAMT $23.70
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- PAMT N/A
- ELDN 45.29
- Support Level
- PAMT N/A
- ELDN $3.68
- Resistance Level
- PAMT N/A
- ELDN $4.19
- Average True Range (ATR)
- PAMT 0.00
- ELDN 0.33
- MACD
- PAMT 0.00
- ELDN -0.05
- Stochastic Oscillator
- PAMT 0.00
- ELDN 26.15
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.